Abstract
Antithrombotic treatment after heart valve surgery is of utmost importance depending on the type of used valve. Since in the early 1960s, oral anticoagulation with vitamin K antagonist are the gold-standard for prevention of thromboembolism at replaced heart valves. The introduction of new oral anticoagulation has dramatically changed treatment strategy in patients with atrial fibrillation and in patients with venous thromboembolism like deep vein thrombosis and pulmonary embolism. However, to date, the use of these newer drugs is contraindicated after implantation of mechanical heart valves for prevention of thromboembolism. Large trial revealed significantly higher rates of thromboembolism and bleeding events as compared to oral anticoagulation. Further studies are required to evaluate the several newer oral anticoagulations in patients with mechanical heart valve.
Keywords: Coumadin, heart valve, novel oral anticoagulation, surgery, warfarin.
Graphical Abstract
Cardiovascular & Hematological Disorders-Drug Targets
Title:New Oral Anticoagulation after Heart Valve Replacement
Volume: 15 Issue: 2
Author(s): Ibrahim El-Battrawy, Stefan Baumann, Aydin Huseynov and Ibrahim Akin
Affiliation:
Keywords: Coumadin, heart valve, novel oral anticoagulation, surgery, warfarin.
Abstract: Antithrombotic treatment after heart valve surgery is of utmost importance depending on the type of used valve. Since in the early 1960s, oral anticoagulation with vitamin K antagonist are the gold-standard for prevention of thromboembolism at replaced heart valves. The introduction of new oral anticoagulation has dramatically changed treatment strategy in patients with atrial fibrillation and in patients with venous thromboembolism like deep vein thrombosis and pulmonary embolism. However, to date, the use of these newer drugs is contraindicated after implantation of mechanical heart valves for prevention of thromboembolism. Large trial revealed significantly higher rates of thromboembolism and bleeding events as compared to oral anticoagulation. Further studies are required to evaluate the several newer oral anticoagulations in patients with mechanical heart valve.
Export Options
About this article
Cite this article as:
El-Battrawy Ibrahim, Baumann Stefan, Huseynov Aydin and Akin Ibrahim, New Oral Anticoagulation after Heart Valve Replacement, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209111735
DOI https://dx.doi.org/10.2174/1871529X1502151209111735 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology Barriers to Achieving Optimal Glycemic Control in a Multi-Ethnic Society: A US Focus
Current Diabetes Reviews High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Recent Drug Development Approaches in Thrombosis, Stroke and other Cardiovascular Diseases
Current Pharmaceutical Design Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Lipoic Acid as a Potential Therapy for Chronic Diseases Associated with Oxidative Stress
Current Medicinal Chemistry A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Combination of a Sterol Absorption Inhibitor and Cardiovascular Agents for the Treatment of Dyslipidemia
Recent Patents on Cardiovascular Drug Discovery Novel Molecules Targeting Dyslipidemia and Atherosclerosis
Current Medicinal Chemistry NPY and Cardiac Diseases
Current Topics in Medicinal Chemistry Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Coenzyme Q10: A Potential Adjunct for Treatment of Antiphospholipid Syndrome and Recurrent Miscarriage
Current Immunology Reviews (Discontinued) Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry Statins in Stroke
Current Medicinal Chemistry Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design